Andere Kunden interessierten sich auch für
![Strengthening the Workforce to Support Community Living and Participation for Older Adults and Individuals with Disabilities]( "Strengthening the Workforce to Support Community Living and Participation for Older Adults and Individuals with Disabilities")
Strengthening the Workforce to Support Community Living and Participation for Older Adults and Individuals with Disabilities51,99 €![Socioeconomic Status and Functional Ability Among Older Adults]( "Socioeconomic Status and Functional Ability Among Older Adults")
Socioeconomic Status and Functional Ability Among Older Adults76,99 €![Providing Healthy and Safe Foods as We Age]( "Providing Healthy and Safe Foods as We Age")
Providing Healthy and Safe Foods as We Age61,99 €![The Drug Development Paradigm in Oncology]( "The Drug Development Paradigm in Oncology")
The Drug Development Paradigm in Oncology62,99 €![Advancing Progress in the Development and Implementation of Effective, High-Quality Cancer Screening]( "Advancing Progress in the Development and Implementation of Effective, High-Quality Cancer Screening")
Advancing Progress in the Development and Implementation of Effective, High-Quality Cancer Screening51,99 €![Addressing the Barriers to Pediatric Drug Development]( "Addressing the Barriers to Pediatric Drug Development")
Addressing the Barriers to Pediatric Drug Development33,99 €![Improving the Health, Safety, and Well-Being of Young Adults]( "Improving the Health, Safety, and Well-Being of Young Adults")
Improving the Health, Safety, and Well-Being of Young Adults56,99 €
There is a void in evidence-based information for making informed decisions on how to optimize care for older adults, particularly those 80 years and over. Because older adults are vastly underrepresented in clinical trials, there is a dearth of information about the appropriate use of drugs in this population. Yet older adults have higher rates of comorbidities and simultaneous use of multiple medications than the general population, and are the majority users of many medications. Additionally, age-related physiological and pathological changes, particularly for adults 80 years of age and older, can lead to significant differences in the pharmacokinetics (PK)2 and pharmacodynamics (PD)3 of a given drug compared to the general population. On August 5 and 6, 2020, the National Academies of Sciences, Engineering, and Medicine hosted a workshop titled Drug Research and Development for Adults Across the Older Age Span. The workshop was designed to examine the challenges and opportunities in drug research and development for older adult populations, explore barriers that impede safety and efficacy studies in these populations, and share lessons learned for better understanding clinical pharmacology for populations over age 65. This publication summarizes the presentation and discussion of the workshop.
Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.